The awards for Innovation and Sustainability “The Golden Tablet” and “Most Innovative Product” have been granted to pharmaceutical companies since 2000. The recipients of the “Golden Tablet” award, also known as the Pharma Accolade, are chosen on the basis of Pharma Trend survey, which identifies the most innovative and sustainable pharmaceutical companies within a field of study. For this survey, which is conducted on behalf of the trade journal Pharma Barometer, doctors with various specializations, pharmacists and patients complete an online questionnaire about sustainability and innovation in the pharmaceutical industry.
Pharma Trend – Image & Innovation Award 2022
On September 13, the winners of the “Golden Tablet” and “Most Innovative Product“ awards were revealed at the “Pharma Trend – Image & Innovation” awards ceremony. Additionally, the Pharma Trend ranking of the best pharmaceutical companies was published for the seventh time.
The Eurecon Verlag event is under the patronage of the Bavarian State Ministry of Health and Care. The keynote speech gave the patron, Bavarian Health Minister Klaus Holetschek. The festive award ceremony was moderated by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).
Partners of the Pharma Trend Image & Innovation Award are Ashfield, Harris Interactive and BioM; sponsors are Bundesverband Mergers & Acquisitions, Business Wire, Dorothea Küsters Life Science Communications, GESDAT, JJ Sustainability, Lucky7even, MCC and tiny web. Media partners of the award ceremony are Apovid, Biermann Medizin, esanum, Healthcare Marketing, Vidal MMI (Gelbe Liste) and PharmaBarometer, the magazine for innovation and sustainability.
Pharma Award: Golden Tablet
The decisive factors in choosing a winner for “The Golden Tablet” Pharma award are the quality of information about the sales force, education events, information on the product and pricing, as well as the companies’ research activities and innovative strength, value for money, and the quality of the products. It appears that doctors place a lot of value on the R&D efforts of the Golden Tablet winners, as well as on transparent information about the companies. Doctors also value the companies’ resistance to corruption highly. In terms of the medications themselves, the most important considerations were the products’ effectiveness and tolerability, and the benefits in treatment observed to date.
“The Golden Tablet” 2022 Award Recipients
The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually among physicians in Germany since 2000 in the Rx category and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 additionally in the Specialty Care category on behalf of the PharmaBarometer magazine. In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their key stakeholders – physicians, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynecologists, oncologists/hematologists, pediatricians and urologists, as well as 100 pharmacists and 600 patients.
This year, the following companies were honored with the “Golden Tablet” award:
- Bionorica (pharmacists)
- BioNTech (general practitioners)
- InfectoPharm (pediatricians)
- Janssen-Cilag (urologists)
- Jenapharm (gynecologists)
“The Golden Tablet” Award Winners since 2000:
| Year | General Practice & Internal Medicine | Neurology | Urology | Dermatology | ENT medicine | Gynecology | Pediatrics | Pneumology | Orthopedics and Rheumatology | Diabetology | Cardiology | Ophthalmology | Oncology | Gastroenterologists | Pharmacists | Patients |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | BioNTech | Janssen-Cilag | Jenapharm | InfectoPharm | Bionorica | |||||||||||
| 2021 | BioNTech | Janssen-Cilag | BioNTech | BioNTech | BioNTech | |||||||||||
| 2020 | Janssen-Cilag | Jenapharm | InfectoPharm | |||||||||||||
| 2019 | Jenapharm | InfectoPharm | Roche | |||||||||||||
| 2018 | Jenapharm | InfectoPharm | Lilly | Ratiopharm | ||||||||||||
| 2017 | Biogen | Astellas | Jenapharm | InfectoPharm | Lilly | Roche | ||||||||||
| 2016 | Janssen-Cilag | Astellas | InfectoPharm | Jenapharm | InfectoPharm | Boehringer Ingelheim | Roche | |||||||||
| 2015 | Biogen | Astellas | Jenapharm | InfectoPharm | Bayer | Roche | ||||||||||
| 2014 | Berlin-Chemie | Biogen | Astellas | Galderma | Jenapharm | InfectoPharm | Novo Nordisk | Roche | ||||||||
| 2013 | Bayer | Janssen-Cilag | Galderma | Jenapharm | InfectoPharm | Novartis | Bayer | |||||||||
| 2012 | Berlin-Chemie | Novartis | Astellas | Basilea | Jenapharm | InfectoPharm | Berlin-Chemie Bayer | Boehringer Ingelheim | Alcon | Roche | ||||||
| 2011 | Novartis | Novartis | Bayer | Basilea | Jenapharm | InfectoPharm | Amgen | Berlin-Chemie | Alcon | Roche | ||||||
| 2010 | Novartis | Janssen-Cilag | Astellas | Basilea | Jenapharm | InfectoPharm | Novartis | MSD | Alcon | Roche | ||||||
| 2009 | Novartis | Janssen-Cilag | Astellas | Basilea | Jenapharm | InfectoPharm | MSD | Novartis | Alcon | Roche | ||||||
| 2008 | Novartis | Janssen-Cilag | Almirall Hermal | Hexal | Jenapharm | InfectoPharm | MSD | MSD | Alcon | Roche | ||||||
| 2007 | MSD | Janssen-Cilag | Astellas | Hexal | Jenapharm | InfectoPharm | MSD | Sanofi - Aventis | Pfizer | Roche | ||||||
| 2006 | AstraZeneca | Janssen-Cilag | Astellas | Novartis | Jenapharm | InfectoPharm | Boehringer Ingelheim | MSD | Sanofi - Aventis | Alcon | ||||||
| 2005 | Pfizer | Eli Lilly | Bayer | Novartis | Jenapharm | InfectoPharm | Boehringer Ingelheim | MSD | Novo Nordisk | Roche | ||||||
| 2004 | Pfizer | Pfizer | Takeda | Hermal | Jenapharm | InfectoPharm | Boehringer Ingelheim | MSD | Novo Nordisk | Aventis | ||||||
| 2003 | Pfizer | Pfizer | Takeda | Hermal | Jenapharm | InfectoPharm | GlaxoSmithKline | MSD | ||||||||
| 2002 | MSD | Janssen-Cilag | Takeda | Essex Pharma | Schering | InfectoPharm | ||||||||||
| 2001 | MSD | Janssen-Cilag | Takeda | Aventis | Aventis | Schering | ||||||||||
| 2000 | MSD | Novartis | Takeda | Hermal | Aventis | |||||||||||
| Year | General Practice & Internal Medicine | Neurology | Urology | Dermatology | ENT medicine | Gynecology | Pediatrics | Pneumology | Orthopedics and Rheumatology | Diabetology | Cardiology | Ophthalmology | Oncology | Gastroenterologists | Pharmacists | Patients |
Pharma Award: Most innovative Product
The effectiveness and tolerability of the products, and the benefits in treatment observed so far are the most decisive criteria in granting for the “Most Innovative Product” award.
Early benefit assessment of medications
The medications suggested by the doctors as the most innovative product were generally introduced in the 36 months prior to the spring release of the annual survey or had received an extension that was significant to the treatment development process. The Pharma Trend results are therefore highly valuable in the early assessment of the benefits of the medications from the users’ perspective in comparison to earlier treatments.
“Most Innovative Product” 2022 Award Recipients
What differentiates the “Most Innovative Product“ award from other accolades in the pharmaceutical industry is its jury: the benefits of the medication are evaluated exclusively by doctors, pharmacist and patients, based on their experience of applying the treatments.
The winners of the awards 2022 are:
- Algovir by Hermes Arzneimittel (pharmacists, patients)
- Cariban by ITF Pharma (gynecologists)
- CDR132L by Cardior Pharmaceuticals (leap innovations)
- Comirnaty by BioNTech (general practitioners, pediatricians)
- DeflaGyn by Exeltis (gynecologists)
- dermanostic by Dermanostic (dermatologists)
- Dulcosoft by Sanofi (pharmacists)
- Enhertu by Daiichi Sankyo (oncologists/hematologists)
- Klisyri by Almirall (dermatologists)
- MyIUS by Jenapharm (gynecologists)
- Nubeqa by Bayer Vital (urologists)
- Oyono by Divapharma (pharmacists)
- Palforzia by Aimmune (allergists)
- Paxlovid by Pfizer (general practitioners)
- Ryeqo by Gedeon Richter (gynecologists)
- Slinda by Exeltis (gynecologists)
- Voxzogo by BioMarin (pediatricians)
“Most Innovative Product” Winners since 2000:
| Year | General Practice & Internal Medicine | Neurology | Urology | Dermatology | ENT medicine | Gynecology | Pediatrics | Pneumology | Orthopedics and Rheumatology | Diabetology | Cardiology | Ophthalmology | Oncology | Gastroenterology | Pain therapists | Orphan Drugs | Specialty care | Pharmacists | Patients | Digital health apps | Diagnostics | Leap Innovations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | Comirnaty Paxlovid | Nubeqa | Klisyri | Palforzia | Cariban DeflaGyn Ryeqo Slinda | Comirnaty | Voxzogo | Enhertu | Algovir Dulcosoft Oyono | Algovir | MyIUS | dermanostic | CDR132L (Cardior Pharmaceuticals) RCS-21 (RNATICS) PAN004 (Pantherna Therapeutics) |
|||||||||
| 2021 | Comirnaty | Erleada | Tolak | Slinda DeflaGyn | Hepcludex Poteligeo Pemazyre | ImmunoBON | Mindable App (General Practice) Mika App (Urology) MyIUS (Gynecology) | SARS-CoV-2 Antigen Test (Roche Diagnostics) AVENIO NGS (Roche Diagnostics) | FYB 207 Formycon ETH 47 Ethris PRS - 220 Pieris |
|||||||||||||
| 2020 | Erleada | Kyleena | Slenyto | Stelara | Moventig | TAKHZYRO | spermidineLIFE Thomapyrin Tension Duo | |||||||||||||||
| 2019 | Kyleena | Slenyto | Stelara Xeljanz | Lynparza TAKHZYRO | Canesten Extra Femannose | BOCAhealth | ||||||||||||||||
| 2018 | Ocrevus | Tremfya | Kyleena | Scabioral | Jardiance | Jorveza | Blincyto Hemlibra | Radionuklide und Radiopharmaka | ||||||||||||||
| 2017 | Ocrevus Zinbryta | Kyleena | Jardiance | Stelara | ||||||||||||||||||
| 2016 | Brintellix | Xtandi | Acarizax | Jardiance | Opdivo | |||||||||||||||||
| 2015 | Forxiga | Tecfidera Lemtrada Brintellix | Xtandi | Esmya | Bexsero | Trulicity | Imbruvica | |||||||||||||||
| 2014 | Forxiga | Tecfidera | Betmiga | Mirvaso | Jaydess | Bexsero | Tresiba | Eylea | Kadcyla | |||||||||||||
| 2013 | Xarelto | Zytiga | Picato | Esmya | Bexsero | Seebri | Eylea | |||||||||||||||
| 2012 | Xarelto | Gilenya | Zytiga | Toctino | Zoely | Infectodexa Krupp | Bydureon | Xarelto | Lucentis | Afinitor Zelboraf | ||||||||||||
| 2011 | Daxas | Gilenya | Levitra | Toctino | Qlaira | Infectodexa Krupp | Prolia | Victoza | Lucentis | Tasigna | ||||||||||||
| 2010 | Pradaxa | Valdoxan | Priligy Duodart | Toctino | Qlaira | Prevenar 13 | Onbrez | Prolia | Lucentis | Nplate Iressa | ||||||||||||
| 2009 | Rasilez | Valdoxan | Priligy | Toctino | Qlaira | Synflorix | Aclasta | Januvia | Lucentis | Avastin | ||||||||||||
| 2008 | Januvia | Invega | Raptiva | Grazax | Gardasil | Gardasil | Aclasta | Januvia | Lucentis | Avastin | ||||||||||||
| 2007 | Exforge | Abilify | Yentreve | Grazax | Gardasil | Gardasil | Bonviva | Byetta | Lucentis | Sutent | ||||||||||||
| 2006 | Inegy | Abilify | Yentreve | Raptiva | Yentreve | Singulair | Xolair | Bonviva | Exubera | Combigan | ||||||||||||
| 2005 | Inegy | Abilify | Yentreve | Raptiva | Yentreve | Singulair | Alvesco | Forsteo | Levemir | Avastin | ||||||||||||
| 2004 | Ezetrol | Cipralex | Cialis | Elidel | NuvaRing | Elidel | Spiriva | Bextra | Lantus | Erbitux | ||||||||||||
| 2003 | Ezetrol | Zeldox | Cialis | Protopic | NuvaRing | Elidel | Spiriva | Fosamax | ||||||||||||||
| 2002 | Vioxx | Zyprexa | Viagra | Protopic | Lafamme | Singulair | ||||||||||||||||
| 2001 | Vioxx | Zyprexa | Viagra | Aerius | Aerius | Yasmin | ||||||||||||||||
| 2000 | Vioxx | Zyprexa | Viagra | Propecia | Nasonex | |||||||||||||||||
| Year | General Practice & Internal Medicine | Neurology | Urology | Dermatology | ENT medicine | Gynecology | Pediatrics | Pneumology | Orthopedics and Rheumatology | Diabetology | Cardiology | Ophthalmology | Oncology | Gastroenterology | Pain therapists | Orphan Drugs | Specialty care | Pharmacists | Patients | Digital health apps | Diagnostics | Startups |
Pharma Barometer “Honorary Award”
As the organizer of the Pharma Trend Image & Innovation Award, Eurecon Verlag has initiated the “Pharma Barometer Ehrenpreis”. This award promotes charitable, sustainable engagement. Since 2005, more than 240,000.00 Euro have supported the work of various organizations, including the following projects, patient groups, organizations and organisators:
- 2019: Anja Gehlken, first chairman of the SCHAKI e.V.
- 2018: Prof. Dr. Wolfgang M. Heckl, General Director German Museum
- 2012: Deutsche Blinden- und Sehbehindertenverband e.V. (DBSV)
- 2011: Deutsche Herzstiftung e.V.
- 2010: Stiftung Deutsche Schlaganfall-Hilfe
- 2009: Brustkrebs Deutschland e.V.
- 2008: Stiftung Kindergesundheit
- 2007: Deutsche Parkinsonvereinigung e.V.
- 2006: Felix Burda Stiftung
- 2005: Aktion Knochenmarkspende Bayern e.V.
